Name in SEC filings: HARROW, INC.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| IHEEZO (QUELL) | /data readout | Stage not stated | in the fourth quarter of 2026 | 8-K · |
| NATACYN | Topline/data readout | Stage not stated | in the fourth quarter of 2026 | 8-K · |
| TRIESENCE Phase 3 | Topline/data readout | Phase 3 | in early 2027 | 8-K · |
Source: ORION, orionbiotechai.com/company/HROW, data as of Oct 17, 2026
https://www.orionbiotechai.com/company/HROW
IHEEZO (QUELL) · Topline/data readout · in the fourth quarter of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutin the fourth quarter of 2026
Stage: Not stated
Public float: $1,004,000,000 · as of · SEC filing
IHEEZO (QUELL): Topline data from QUELL, a prospective, randomized, multi-center clinical trial evaluating IHEEZO in patients undergoing intravitreal injections, are expected in the fourth quarter of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the fourth quarter of 2026
Stage: Not stated
Public float: $1,004,000,000 · as of · SEC filing
NATACYN®: The first patients were enrolled in an investigator-initiated clinical study during the second quarter, with topline data expected in the fourth quarter of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin early 2027
Stage: Phase 3SEC filing · “Phase 3”
Public float: $1,004,000,000 · as of · SEC filing
TRIESENCE: The Company’s Phase 3 trial evaluating TRIESENCE for the treatment of ocular inflammation and pain following cataract surgery is on track to fully enroll in 2026, with topline data expected in early 2027.
8-K · Filed · Last checked
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| IHEEZO (QUELL)Clinical results | in the fourth quarter of 2026“IHEEZO (QUELL): Topline data from QUELL, a prospective, randomized, multi-center clinical trial evaluating IHEEZO in patients undergoing intravitreal injections, are expected in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| NATACYNClinical results | in the fourth quarter of 2026“NATACYN®: The first patients were enrolled in an investigator-initiated clinical study during the second quarter, with topline data expected in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| TRIESENCE Phase 3Clinical results | in early 2027“TRIESENCE: The Company’s Phase 3 trial evaluating TRIESENCE for the treatment of ocular inflammation and pain following cataract surgery is on track to fully enroll in 2026, with topline data expected in early 2027.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for HROW. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See HROW in the calendar · Review labels and methodology